Laxxon Medical Reports Promising Results for Oral GLP-1 Dosage Form

Laxxon Medical, specializing in advanced oral drug delivery systems, announced successful pilot pharmacokinetic (PK) study results for its oral GLP-1 agonist, LXM.2. Conducted in pigs, the study revealed a significant 10-fold increase in bioavailability compared to existing products.

The oral GLP-1 tablet aims to change diabetes and weight loss treatment with a daily alternative to injections, incorporating a permeation enhancer for optimal absorption. Future studies will explore its microtablet format to further enhance effectiveness.

Chief Operations Officer Klaus Kühne highlighted the innovation's potential for patient compliance, facilitated by their 3D screen printing technology. CEO Helmut Kerschbaumer emphasized their commitment to revolutionizing medicine.

Laxxon's proprietary SPID®-Technology enables the production of microtablets with improved bioavailability, controlled release, and flexible administration, offering significant patient benefits.